CMPXCompass TherapeuticsRunning, no new patients
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract Cancer · Cholangiocarcinoma · Gall Bladder Cancer · Ampullary Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 168 (final count)
- Started
- Jan 9, 2023
- Main results expected
- Aug 31, 2027
- Fully finished
- Aug 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Best Overall Response
Measured over: From randomization to treatment discontinuation for any reason, average 6 months
Changes Tremor has spotted
Reworded the trial's main goal or its timing.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-06 15:29 UTC · primary_outcome_reworded · primary_outcomes
old: [{"measure":"Best Overall Response","timeFrame":"From randomization to treatment discontinuation for any reason, average 6 months","description":"Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR) as assessed by RECIST 1.1"}]
new: [{"measure":"Best Overall Response","timeFrame":"From randomization to treatment discontinuation for any reason, average 6 months","description":"Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \\>=30% decrease in the sum of the longest diameter of target lesions."}]
Trial ID NCT05506943 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC